CLINICAL TRIALS AND OBSERVATIONS First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial

نویسندگان

  • Anton Hagenbeek
  • Ole Gadeberg
  • Peter Johnson
  • Lars Møller Pedersen
  • Jan Walewski
  • Andrzej Hellmann
  • Brian K. Link
  • Tadeusz Robak
  • Marek Wojtukiewicz
  • Michael Pfreundschuh
  • Michael Kneba
  • Andreas Engert
  • Pieter Sonneveld
  • Mimi Flensburg
  • Jørgen Petersen
  • Nedjad Losic
  • John Radford
چکیده

1University Medical Center Utrecht, Department of Hematology, Utrecht, The Netherlands; 2Vejle Hospital, Vejle, Denmark; 3Southampton General Hospital, Southampton, United Kingdom; 4Herlev University Hospital, Herlev, Denmark; 5Maria Sklodowska-Curie Memorial Institute & Cancer Centre, Warsaw, Poland; 6Medical University of Gdansk, Department of Hematology, Gdansk, Poland; 7University of Iowa, College of Medicine, Iowa City; 8Medical University of Lodz, Department of Hematology, Lodz, Poland; 9Comprehensive Cancer Center, Department of Medical Oncology, Bialystok, Poland; 10Saarland University Medical School, Department of Internal Medicine I, Homburg, Germany; 11University of Kiel, Department of Internal Medicine, Kiel, Germany; 12University Hospital of Cologne, Cologne, Germany; 13Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands; 14Genmab, Copenhagen, Denmark; and 15Christie Hospital and University of Manchester, Manchester, United Kingdom

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Treatment of relapsed CD20 Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group

This phase 2 trial was performed to evaluate the safety and efficacy of the chimeric monoclonal anti-CD20 antibody rituximab in patients with relapsed lymphocyte-predominant Hodgkin lymphoma or other CD20 subtypes of Hodgkin disease (HD). Eligibility criteria required expression of the CD20 antigen on more than 30% of malignant cells. Fourteen patients were treated with 4 weekly intravenous inf...

متن کامل

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas

Patients with peripheral T-cell lymphomas (PTLs) have an extremely poor prognosis when relapsed or refractory to conventional chemotherapy. We have studied alemtuzumab, a humanized anti-CD52 monoclonal antibody, as therapy for patients with heavily pretreated and refractory PTL. Fourteen patients entered the study. All had clinical stage III or IV disease. Patients received a rapidly escalating...

متن کامل

CLINICAL TRIALS AND OBSERVATIONS Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients

Radioimmunotherapy of indolent nonHodgkin lymphoma (NHL) has achieved objective response rates in clinical trials comparable with standard rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy, but is relatively underused in routine practice. In this article, we report our clinical experience in 142 consecutive patients who received iodine-131 rituximab radioimm...

متن کامل

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial

Mildly thrombocytopenic patients with relapsed or refractory low-grade nonHodgkin lymphoma (NHL) have an increased risk of chemotherapy-induced myelosuppression following treatment. The safety and efficacy of radioimmunotherapy with a reduced dose of 90Y ibritumomab tiuxetan (0.3 mCi/kg [11 MBq/kg]; maximum 32 mCi [1.2 GBq]) was evaluated in 30 patients with mild thrombocytopenia (100-149 109 p...

متن کامل

CLINICAL TRIALS AND OBSERVATIONS The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma

Given the significant activity and tolerability of bendamustine, rituximab, and bortezomib in patients with relapsed indolent and mantle cell non-Hodgkin lymphoma, and laboratory studies suggesting synergistic activity, we conducted a multicenter phase 2 study of the bendamustine/ bortezomib/rituximab combination. Patients with relapsed or refractory indolent and mantle cell lymphoma with adequ...

متن کامل

ذخیره در منابع من

ذخیره در منابع من قبلا به منابع من ذحیره شده

{@ msg_add @}


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2008